The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL.

STAT4 T-PLL T-cell lymphoma cell proliferation leukemogenesis miR-141 miR-200c

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Apr 2023
Historique:
received: 27 03 2023
revised: 17 04 2023
accepted: 25 04 2023
medline: 13 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

T-prolymphocytic leukemia (T-PLL) is a rare and mature T-cell malignancy with characteristic chemotherapy-refractory behavior and a poor prognosis. Molecular concepts of disease development have been restricted to protein-coding genes. Recent global microRNA (miR) expression profiles revealed miR-141-3p and miR-200c-3p (miR-141/200c) as two of the highest differentially expressed miRs in T-PLL cells versus healthy donor-derived T cells. Furthermore, miR-141/200c expression separates T-PLL cases into two subgroups with high and low expression, respectively. Evaluating the potential pro-oncogenic function of miR-141/200c deregulation, we discovered accelerated proliferation and reduced stress-induced cell death induction upon stable miR-141/200c overexpression in mature T-cell leukemia/lymphoma lines. We further characterized a miR-141/200c-specific transcriptome involving the altered expression of genes associated with enhanced cell cycle transition, impaired DNA damage responses, and augmented survival signaling pathways. Among those genes, we identified

Identifiants

pubmed: 37173993
pii: cancers15092527
doi: 10.3390/cancers15092527
pmc: PMC10177500
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Union
ID : ERANET-PLL (01KT1906A)
Organisme : European Union
ID : JAKSTAT-TARGET (ERAPERMED2018-066)
Organisme : Deutsche José Carreras Leukämie-Stiftung
ID : DJCLS 03 F/2016
Organisme : Köln Fortune Stiftung
ID : individual scholarships
Organisme : Academy of Finland
ID : 326238
Organisme : Academy of Finland
ID : 345803

Références

Cancers (Basel). 2019 Nov 21;11(12):
pubmed: 31766351
Nucleic Acids Res. 2014;42(17):e133
pubmed: 25063298
RNA. 2007 Jan;13(1):22-9
pubmed: 17123955
Blood. 2008 Jan 1;111(1):328-37
pubmed: 17890451
Nat Rev Immunol. 2011 Apr;11(4):239-50
pubmed: 21436836
J Oncol. 2021 Oct 12;2021:5425491
pubmed: 34675977
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
Oncogene. 2000 May 15;19(21):2577-84
pubmed: 10851056
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
pubmed: 16166262
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Cancers (Basel). 2022 Apr 18;14(8):
pubmed: 35454943
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638338
Cancer Res. 2004 Oct 15;64(20):7579-87
pubmed: 15492285
Mol Cell. 2004 Jul 23;15(2):185-97
pubmed: 15260970
Sci Rep. 2017 Oct 19;7(1):13598
pubmed: 29051585
Mol Aspects Med. 2019 Dec;70:57-71
pubmed: 31558294
Cancers (Basel). 2021 Nov 23;13(23):
pubmed: 34884985
Cancer Res. 2022 May 3;82(9):1818-1831
pubmed: 35259248
Haematologica. 2022 Jan 01;107(1):187-200
pubmed: 33543866
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genes (Basel). 2021 Feb 12;12(2):
pubmed: 33673143
J Invest Dermatol. 2018 Sep;138(9):2024-2032
pubmed: 29559342
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Clin Cancer Res. 2014 Jun 1;20(11):2851-61
pubmed: 24727323
Lab Invest. 2008 Aug;88(8):856-64
pubmed: 18521064
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
J Cell Physiol. 2018 Aug;233(8):5574-5588
pubmed: 29521426
World J Gastroenterol. 2015 Apr 7;21(13):3983-93
pubmed: 25852285
Oncotarget. 2016 Nov 8;7(45):73558-73572
pubmed: 27713153
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Blood. 2004 Jul 15;104(2):328-35
pubmed: 15044256
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Perspect Clin Res. 2016 Apr-Jun;7(2):68-74
pubmed: 27141472
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Blood. 2019 Oct 3;134(14):1132-1143
pubmed: 31292114
J Exp Clin Cancer Res. 2018 Jan 31;37(1):18
pubmed: 29386059
Science. 2010 Jan 8;327(5962):198-201
pubmed: 19965718
J Immunol. 2002 Oct 15;169(8):4388-98
pubmed: 12370372
Oncotarget. 2016 Aug 30;7(35):57086-57098
pubmed: 27494881
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Oncol Lett. 2021 Feb;21(2):137
pubmed: 33552256
Ann Oncol. 2017 Jul 01;28(7):1554-1559
pubmed: 28379307
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124
pubmed: 32034661
Oncotarget. 2015 Mar 30;6(9):6472-98
pubmed: 25762624
Onco Targets Ther. 2021 Jan 05;13:13479-13490
pubmed: 33447052
Cell Cycle. 2014;13(18):2975-82
pubmed: 25486484
Int J Cancer. 2009 Apr 15;124(8):1756-66
pubmed: 19115200
Oncol Lett. 2019 Oct;18(4):3994-4007
pubmed: 31565080
Haematologica. 2022 Jan 01;107(1):143-153
pubmed: 33596640

Auteurs

Moritz Otte (M)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.

Johanna Stachelscheid (J)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.

Markus Glaß (M)

Section for Molecular Cell Biology, Institute of Molecular Medicine, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Charles Tanford Protein Center, 06120 Halle, Germany.

Linus Wahnschaffe (L)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.

Qu Jiang (Q)

Department of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, 04103 Leipzig, Germany.

Waseem Lone (W)

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Aleksandr Ianevski (A)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland.

Tero Aittokallio (T)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Institute for Cancer Research, Oslo University Hospital, Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, 0372 Oslo, Norway.

Javeed Iqbal (J)

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Michael Hallek (M)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.
Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany.

Stefan Hüttelmaier (S)

Section for Molecular Cell Biology, Institute of Molecular Medicine, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Charles Tanford Protein Center, 06120 Halle, Germany.

Alexandra Schrader (A)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.
CIRI, Centre International de Recherche en Infectiologie, Team Lymphoma ImmunoBiology, INSERM, U1111 CNRS UMR 5308, University of Lyon, Université Claude Bernard Lyon 1, 69364 Lyon, France.

Till Braun (T)

Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, 50937 Cologne, Germany.

Marco Herling (M)

Department of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, 04103 Leipzig, Germany.

Classifications MeSH